Campbell David Alan 4
4 · Janux Therapeutics, Inc. · Filed Dec 27, 2024
Insider Transaction Report
Form 4
Campbell David Alan
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-12-24$56.19/sh−25,000$1,404,805→ 217,054 total
Footnotes (2)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.
- [F2]The weighted average sale price for the transaction reported was $56.1922 and the range of prices were between $56.00 and $56.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.